New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePancragen vs Vialox

Pancragen vs Vialox

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Pancragen
Skin & CosmeticAnti-Aging & Longevity
Vialox
Summary
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
Vialox is a synthetic pentapeptide that mimics the activity of conotoxin from cone snails, acting as an antagonist of nicotinic acetylcholine receptors at the neuromuscular junction. Similar to Syn-Ake but derived from cone snail venom biochemistry, it reduces facial muscle contraction to smooth expression wrinkles.
Half-Life
Short (minutes); sustained gene-regulatory effects
Not applicable (topical; effect duration hours)
Admin Route
SubQ, Oral
Topical
Research
Typical Dose
10 mg per day
0.005-0.05% in formulation
Frequency
Daily for 10–30 days
Twice daily
Key Benefits
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
  • Reduces dynamic wrinkles from repetitive facial expressions
  • Reversible muscle-relaxing effect without injection
  • Smooths forehead, periorbital, and perioral lines
  • Complementary to collagen-stimulating peptides
  • Well-studied tolerability in cosmetic concentrations
  • Can be combined with Syn-Ake for dual conotoxin/viper venom effect
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
  • Generally very well-tolerated topically
  • Rare contact sensitivity or mild irritation
  • No clinically significant systemic neuromuscular effects at cosmetic doses
Stacks With